Case Comprehensive Cancer Center Support Grant

案例综合癌症中心支持补助金

• 批准号: 10784804
• 负责人: GARY K SCHWARTZ
• 金额: $ 567.32万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-08-01 至 2025-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10784804
• 关键词: African American population; Barrett Esophagus; Basic Cancer Research; Behavioral; Cancer Center; Cancer Center Support Grant; Cancer Detection; Cancer Patient; Cancer Research Infrastructure; Caring; Catchment Area; Clinic; Clinical; Clinical Research; Clinical Trials; Clinics and Hospitals; Collaborations; Colon Carcinoma; Communities; Community Outreach; Comprehensive Cancer Center; Decision Making; Dedications; Diagnosis; Disease; Dissemination and Implementation; Family; Focus Groups; Funding; General Population; Genetic Risk; Genomics; Goals; Grant; Growth; Health; Hospitals; Human; Infrastructure; Institution; Intervention; Laboratories; Leadership; Link; Malignant Neoplasms; Medical Research; Mission; Molecular Abnormality; NCI-Designated Cancer Center; Newly Diagnosed; Ohio; Outpatients; Patients; Population; Population Research; Prevention; Protons; Quality of Care; Research; Research Activity; Research Personnel; Resource Sharing; Schools; Scientist; Site; Solid; Speed; Survivors; Therapeutic; Tobacco smoking behavior; Translational Research; Translations; Universities; University Hospitals; Update; anticancer research; bench to bedside; cancer care; cancer therapy; clinical application; drug discovery; high-throughput drug screening; improved; innovation; inter-institutional; investigator-initiated translational research; leukemia; low socioeconomic status; meetings; member; new therapeutic target; novel; programs; survivorship; therapeutic target

OVERALL PROJECT SUMMARY/ABSTRACT The mission of Case Comprehensive Cancer Center (Case CCC), now in its 27th grant year, is to promote a coordinated, translational research-oriented culture of scientific discovery applied to human cancers, that improves cancer detection, prevention, treatment, cure, and survivorship in Cleveland, Northeast Ohio and around the world, and to disseminate its advances to patients and populations. The Center provides leadership and oversight of collaboration for basic cancer research oriented toward identification of novel therapeutic targets; prevention, control and population research; therapeutic and non-therapeutic clinical research across the disease spectrum; and community outreach. These accomplishments include examples of practice changing impact within the catchment area and nationally. The Center coordinates all aspects of cancer research in Cleveland and Northern Ohio, including activities of the affiliate institutions of Case Western Reserve University, Cleveland Clinic, and University Hospitals. The Center provides opportunities to participate in clinical trials to almost 16,000 cancer patients (over 62% of cancer cases in the catchment area) who are newly diagnosed annually in the region. The Case CCC is organized around 7 Research Programs, 13 Shared Resources, and a clinical and behavioral cancer research infrastructure that prioritizes innovative translational research and investigator-initiated clinical trials that cut across the Research Programs. The Case CCC includes 279 members (172 Full, 32 Associate, and 75 Clinical) from 7 schools and 68 academic departments who actively participate in Center activities including Program and Shared Resource meetings and retreats, and leadership committees, each promoting a transdisciplinary approach that facilitates discovery and clinical application. The cancer focus of the Center is exceptional, with over $77M in direct funding and over $26M in direct NCI funding. Institutional commitment is also exceptional, codified through an updated Memorandum of Understanding. The consortium members will provide over $128M of internal funds for cancer research in the next grant cycle. The Case CCC and its affiliate institutions have established an outstanding infrastructure that enables its members to improve the prevention, diagnosis, and treatment of cancer through discovery, implementation and dissemination, and collaborative transdisciplinary research while providing state-of-the-art care and treatment to cancer patients and their families. The Case CCC yields tangible benefits as an active partner with the NCI by supporting cancer relevant scientific research with direct benefit to patients and the general public.

全面的 项目摘要/摘要 案例综合癌症中心（CASE CCC）的任务已在其第27个赠款中，是为了促进 以人类癌症的协调，以研究为导向研究的科学发现文化 改善在克利夫兰，俄亥俄州东北部的癌症检测，预防，治疗，治愈和生存 在世界各地，并将其进步传播给患者和人群。该中心提供领导 对基础癌症研究协作的监督，旨在鉴定新的治疗性 目标；预防，控制和人口研究；跨治疗和非治疗性临床研究 疾病谱；和社区宣传。这些成就包括实践的例子 在集水区和全国范围内改变影响。该中心协调癌症的各个方面 克利夫兰和俄亥俄州北部的研究，包括案件西部的分支机构机构的活动 储备大学，克利夫兰诊所和大学医院。该中心提供了参加的机会 在临床试验中，近16,000名癌症患者（集水区中62％以上的癌症病例超过62％） 每年在该地区新诊断。案件CCC组织在7个研究计划左右，共享13个 资源以及临床和行为癌症研究基础设施，优先考虑创新的翻译 研究和研究者发起的临床试验，跨越了研究计划。案例CCC 包括来自7所学校和68个学术部门的279名成员（172名成员，32名助理和75个临床） 积极参加中心活动，包括计划和共享资源会议和务虚会， 和领导委员会，每个委员会都促进跨学科方法，以促进发现和临床 应用。该中心的癌症重点非常出色，直接资金超过7700万美元，超过2600万美元 直接NCI资金。机构承诺也是非凡的，是通过更新的备忘录进行编纂的 理解。财团成员将为癌症研究提供超过1.28亿美元的内部资金 下一个赠款周期。案件CCC及其会员机构已经建立了一个出色的基础设施， 使其成员能够通过发现改善癌症的预防，诊断和治疗， 实施和传播以及协作的跨学科研究，同时提供最先进的 照顾和治疗癌症患者及其家人。案件CCC可以作为一个积极的好处 通过支持癌症相关的科学研究，与患者的直接利益和 公众。

项目成果

Synergistic actions of hematopoietic and mesenchymal stem/progenitor cells in vascularizing bioengineered tissues.

• DOI: 10.1371/journal.pone.0003922
• 发表时间: 2008
• 期刊: PloS one
• 影响因子: 3.7
• 作者: Moioli EK;Clark PA;Chen M;Dennis JE;Erickson HP;Gerson SL;Mao JJ
• 通讯作者: Mao JJ

FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapies.

• DOI: 10.18632/oncotarget.1027
• 发表时间: 2013-05
• 期刊: Oncotarget
• 作者: Cipriano R;Miskimen KL;Bryson BL;Foy CR;Bartel CA;Jackson MW
• 通讯作者: Jackson MW

Critical roles for α/β hydrolase domain 5 (ABHD5)/comparative gene identification-58 (CGI-58) at the lipid droplet interface and beyond.

• DOI: 10.1016/j.bbalip.2017.07.016
• 发表时间: 2017-10
• 期刊: Biochimica et biophysica acta. Molecular and cell biology of lipids
• 作者: Brown AL;Mark Brown J
• 通讯作者: Mark Brown J

Oncostatin-M and OSM-Receptor Feed-Forward Activation of MAPK Induces Separable Stem-like and Mesenchymal Programs.

MAPK 的制瘤素-M 和 OSM 受体前馈激活诱导可分离的干细胞样和间充质程序。

• DOI: 10.1158/1541-7786.mcr-22-0715
• 发表时间: 2023
• 期刊: Molecular cancer research : MCR
• 作者: Polak,KelseyL;Tamagno,Ilaria;Parameswaran,Neetha;Smigiel,Jacob;Chan,ERicky;Yuan,Xueer;Rios,Brenda;Jackson,MarkW
• 通讯作者: Jackson,MarkW

RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells.

RNF126 作为浸润性乳腺癌预后不良的生物标志物以及 CHEK1 抑制剂在乳腺癌细胞中的功效

• DOI: 10.1158/1078-0432.ccr-17-2242
• 发表时间: 2018-04-01
• 期刊: Clinical cancer research : an official journal of the American Association for Cancer Research
• 作者: Yang X;Pan Y;Qiu Z;Du Z;Zhang Y;Fa P;Gorityala S;Ma S;Li S;Chen C;Wang H;Xu Y;Yan C;Ruth K;Ma Z;Zhang J
• 通讯作者: Zhang J